Senescing Human Bone-Marrow-Derived Clonal Mesenchymal Stem Cells Have Altered Lysophospholipid Composition and Functionality

Mesenchymal stem cells (MSCs) have
been used in a wide range of
research and clinical studies because MSCs do not have any ethical
issues and have the advantage of low carcinogenicity due to their
limited proliferation. However, because only a small number of MSCs
can be obtained from the bone marrow, ex vivo amplification is inevitably
required. For that reason, this study was conducted to acquire the
metabolic information to examine and control the changes in the activities
and differentiation potency of MSCs during the ex vivo culture process.
Endogenous metabolites of human bone-marrow-derived clonal MSCs (hcMSCs)
during cellular senescence were profiled by ultraperformance liquid
chromatography/quadrupole time-of-flight mass spectrometry (UPLC/QTOFMS).
To select significant metabolites, we used the linear mixed effects
model having fixed effects for batch and time (passage) and random
effects for metabolites, determining the mean using a t test and the standard deviation using an F test. We used structural
analysis with representative standards and spectrum patterns with
different collision energies to distinctly identify eight metabolites
with altered expression during senescence as types of lysophosphatidylcholine
(LPC) and lysophosphatidylethanolamine (LPE), such as LPC 16:0 and
LPE 22:4. The present study revealed changes in endogenous metabolites
and mechanisms due to senescence.